Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9794607 | 0.86 | KMT2A (0.48) | KMT2AOPRK1MEN1VCAM1ABCG2 | |
| SCHEMBL940754 | 0.84 | ACHE (0.47) | KMT2AOPRK1MEN1VCAM1ABCG2 | |
| SCHEMBL19877148 | 0.79 | KDM4E (0.48) | KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL19877274 | 0.79 | LMNA (0.49) | KMT2AMEN1HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4962418 | 0.77 | MAP3K8 (0.59) | ABCG2ALDH1A1POLBLMNARAB9A | |
| SCHEMBL19889943 | 0.76 | RXFP1 (0.58) | KMT2AMEN1HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL19877209 | 0.76 | CASP3 (0.44) | HTTSMN1; SMN2POLBLMNA | |
| SCHEMBL6505699 | 0.75 | KMT2A (0.63) | KMT2AOPRK1MEN1HTTSMN1; SMN2 | |
| SCHEMBL19889941 | 0.74 | KDM4E (0.60) | KMT2AMEN1HTTALDH1A1POLB | |
| SCHEMBL9794632 | 0.73 | ALDH1A1 (0.44) | KMT2AOPRK1MEN1VCAM1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101223143-A | 3-cyanoquinoline inhibitors of TPL2 kinase and methods of making and using the same | WYETH CORP (US) | 2008-07-16 | — | — | CN | disclosed |
| EP-1888529-A2 | 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | Wyeth (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2006-11-23 | — | — | US | disclosed |
| WO-2006124692-A2 | 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | TNNI3K, CSNK1A1L, CDKL1 | KMT2A 1686/4885OPRK1 653/4885MEN1 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.